Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2022 pubmed 10 citations

Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.

Ramirez-Torres. Adela A; Reagan. Allison L AL; Howard. Lauren E LE; Wiggins. Emily E; Vidal. Adriana C AC; Wan. Junxiang J; Miller. Brendan B; Freedland. Stephen J SJ; Cohen. Pinchas P

Key Findings

  • Higher humanin, SHLP2, and MOTS‑c levels were associated with reduced prostate cancer risk in European‑American men
  • African‑American men had lower levels of SHLP2 and MOTS‑c and showed no protective association
  • Racial differences in these mitochondrial peptides may help explain prostate cancer health disparities

Practical Outcomes

  • For biohackers, the findings hint that measuring humanin and related peptides could serve as a biomarker for prostate health, especially in European‑American men. However, there’s no clear protocol for safely raising these peptide levels, so any supplementation or lifestyle changes remain speculative until more research confirms benefits.

Summary

The study found that higher levels of the mitochondrial peptide humanin (and related peptides) are linked to a lower chance of prostate cancer in European‑American men, but this link wasn’t seen in African‑American men, who also tend to have lower peptide levels. This suggests the peptides might play a role in the higher prostate cancer risk seen in African‑American men.

Abstract

The mitochondrial genome has small open reading frames (sORF) which produce measurable mitochondrial-derived peptides (MDPs), including humanin, SHLP2, and MOTS-c. Previously, among men undergoing prostate biopsy, we found higher serum SHLP2 was linked with lower prostate cancer (PC) risk in European American men (EAM), while null associations were found in African American men (AAM). Here, in different patients undergoing prostate biopsy, we tested the link between SHLP2, humanin and MOTS-c and PC risk by race. Plasma SHLP2, humanin, and MOTS-c were measured in 198 men (50/49 EAM/AAM cases; 50/49 EAM/AAM controls) undergoing biopsy. Logistic and multinomial regression models tested associations between each MDP and PC diagnosis, low-grade (grade group, GG1) and high-grade (GG2-5). Models were adjusted for age, body mass index, digital rectal examination, and prostate specific antigen (PSA). We tested interactions between MDPs and race. Among controls, humanin was similar by race (p = 0.60), but both SHLP2 (p = 0.007) and MOTS-c (p = 0.026) were lower in AAM controls versus EAM controls. Among EAM, higher MDP values were associated with lower PC risk (all p ≤ 0.001), with null associations in AAM (all p-interactions ≤ 0.01). Similarly, higher MDP expression was associated with decreased risk of low- and high-grade PC in EAM (all p ≤ 0.005) with null associations in AAM. Higher MDP levels were associated with lower PC risk in EAM but not AAM. Generally, AAM controls had lower MDP levels. These data support MDPs and mitochondrial dysfunction in PC, suggesting greater dysfunction in AAM may contribute to excess PC risk. Future larger studies are needed to confirm these results.

Study Information

Provider

pubmed

Year

2022

Date

2022-07-05T00:00:00.000Z

DOI

10.1002/pros.24398

Citations

10

References

34